Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx

Analysis of Swallowing, Speech and Quality of Life of Patients With Stage T3-T4 Squamous Cell Carcinoma of the Oropharynx Before and After Multimodal Treatment With Curative Intent

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02552550

Enrollment

Registered

2015-09-17

Start date

2013-07-25

Completion date

2016-09-20

Last updated

2018-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous Cell Carcinoma of the Oropharynx

Keywords

squamous cell carcinoma of the oropharynx, swallowing, speech, quality of life

Brief summary

The curative treatment and organ preservation in advanced squamous cell carcinoma of the oropharynx is multimodal. It involves induction chemotherapy and depending on the response radio-chemotherapy or surgery. The combination of these methods has important functional consequences. The aim of this prospective pilot study is to describe swallowing, speech, but also patients' quality of life before and after therapeutic management (existing studies measuring these functions after treatment but not before).

Detailed description

This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak then, as in normal practice, after 3, 6 and 12 months after treatment.

Interventions

PROCEDUREAbility to swallow, speak and quality of life

This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patient with stage T3 or T4 squamous cell carcinoma of the oropharynx previously untreated. * Performance status 0 or 1 * Tumor histology proving squamous cell carcinoma

Exclusion criteria

* Visceral metastases at initial assessment * Contraindication to surgery and / or chemotherapy such as: * A history of other cancer (except basal cell carcinoma skin or cervical cancer in situ) * 2nd associated cancer

Design outcomes

Primary

Measure	Time frame	Description
change from swallowing disorder	between day 0 and 1 year	A swallowing disorder will be determined by conducting a video-endoscopy and voluntary swallowing reflex (composite measure)

Secondary

Measure	Time frame	Description
Change from phonation disorder	between day 0 and 1 year	Phonation disorders will be evaluated by the scale Voice Handicap Index (composite measure)
Change from quality of life	between day 0 and 1 year	The quality of life will be assessed by the Quality of Life scale EORTC QLQ-C30 and QLC-HN35 (composite measure)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026